EGFR and neoplasm: In 224 patients with EGFR-mutant lung adenocarcinoma treated with EGFR-TKIs, the tumor burden, expressed as the number of metastatic sites at EGFR-TKI treatment, and rapid tumor progression at progressive disease (PD) were predictive of inferior survival in patients with lung adenocarcinoma with activating EGFR mutations (27).